

ASX Announcement

Date of AGM and Closing Date for Director Nominations

6 October 2025 – Race Oncology Limited (“Race”) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held at 12.00 noon AEDT on Monday, 24 November 2025 at the Library Auditorium, State Library NSW, 1 Shakespeare Place, Sydney, New South Wales, Australia.

An item of business at the AGM will be the re-election and appointment of Directors. In accordance with clause 15.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Monday, 13 October 2025.

Any nominations must be received by the Company in writing by no later than 5.00 pm AEDT on Monday, 13 October 2025.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile.

Race is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on combinations with an anthracycline (doxorubicin), where we aim to deliver both cardioprotection and enhanced anticancer activity in solid tumour indications. Race is also exploring the use of RC220 as a low intensity treatment for acute myeloid leukaemia and other cancers.

Race Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au